Drug Trial Radar · NCT05126888
SCI-110 in the Treatment of Tourette Syndrome
Last checked: Nov 19, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
164
Planned (sponsor's estimate)
Start
Jun 2026
Primary completion
Oct 2027
Study completion Feb 2028
Sponsor
- Lead sponsor
- Neurothera Labs Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 19, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy, safety and tolerability of the cannabinoid-based medication SCI-110 compared to placebo in subjects with Tourette syndrome.
Conditions
- Tourette Syndrome
Interventions
SCI-110Drug
SCI-110 - a softgel capsule containing Dronabinol and Palmitoylethanolamide (PEA) in the following doses: 2.5mg Dronabinol+400mg PEA, 5mg Dronabinol+400mg PEA and 10mg Dronabinol+400mg. Maximum dose 20mg Dronabinol and 800mg PEA a day.
PlaceboOther
Pill that matches in taste, odour and appearance to SCI-110 active pills
Primary outcomes
What the sponsor says the trial is designed to measure.
- Absolute change from baseline in revised version of Yale Global Tic Severity Scale -Revised - (YGTSS-R-TTS)Time frame: At baseline and 12 weeks after start of treatment in both arms.
Locations
3 sites in 3 countries. Site status is shown where the registry gives one.
Yale Child Study Center - NIHB 205
New Haven, Connecticut
Medizinische Hochschule Hannover
Hanover, Germany
Neurological Institute, Tel Aviv Sourasky Medical Center
Tel Aviv, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.